Compare · NVO vs PVLA
NVO vs PVLA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Palvella Therapeutics Inc. (PVLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PVLA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 94.7x PVLA ($1.83B).
- Over the past year, NVO is down 28.6% and PVLA is up 64.2% - PVLA leads by 92.8 points.
- PVLA has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 17 for PVLA).
- Company
- Novo Nordisk A/S
- Palvella Therapeutics Inc.
- Price
- $38.82-1.05%
- $120.68-5.56%
- Market cap
- $173.66B
- $1.83B
- 1M return
- -10.14%
- -21.42%
- 1Y return
- -28.57%
- +64.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 17
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest PVLA
- William Blair initiated coverage on Palvella Therapeutics
- Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
- SEC Form 4 filed by Palvella Therapeutics Inc.
- SEC Form 144 filed by Palvella Therapeutics Inc.
- Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
- U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
- Chardan Capital Markets resumed coverage on Palvella Therapeutics with a new price target
- Chief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $654,923 worth of shares (4,302 units at $152.24) as part of a pre-agreed trading plan (SEC Form 4)
- Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth